MBX Biosciences Doses First Patient in Phase 3 oPTimize Trial of Canvuparatide
Carmel, Indiana and Burlington, Massachusetts – August 27, 2026 MBX Biosciences announced that the first patient has been dosed...
Orphan Drug
Advertisement
Propanc Advances PRP After Strong Preclinical Pancreatic Cancer Results
Melbourne, Australia – August 27, 2026 Propanc Biopharma announced new preclinical and early translational data for PRP in pancreatic...
Priovant Wins FDA Approval for Lisraya in Dermatomyositis
SILVER SPRING, MARYLAND, Aug 27, 2026 Priovant Therapeutics Inc. has received U.S. Food and Drug Administration (FDA) approval for...
FDA Approves Janssen’s Imaavy for Rare Blood Disorder
SILVER SPRING, MARYLAND, Aug 26, 2026 The U.S. Food and Drug Administration (FDA) has approved Imaavy (nipocalimab-aahu) injection for...
Protagenic Advances PT00114 Toward FDA IND Submission
New York, New York, USA, August 20, 2026 Protagenic Therapeutics, a clinical-stage biopharmaceutical company developing peptide-based treatments for stress-related...
Advertisements
Werewolf Therapeutics and Ambros Announce $150M Merger
Waltham, Massachusetts, USA, and San Diego, California, USA, August 21, 2026 Werewolf Therapeutics and Ambros Therapeutics have announced a...
PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy Program
Warren, New Jersey, August 12, 2026 PTC Therapeutics announced that it was selected as the winning bidder to acquire...
Mereo BioPharma Advances Alvelestat Toward Phase 3 Trial
LONDON, UK; SOLANA BEACH, California; and AHMEDABAD, India, August 11, 2026 Mereo BioPharma Group plc and Sentynl Therapeutics, Inc.,...
Definium Therapeutics Reports Positive Phase 3 GAD Results
NEW YORK, August 12, 2026 Definium Therapeutics, Inc. announced positive topline results from the Phase 3 Voyage study evaluating...
Alterity Expands ATH434 Potential in Neurodegenerative Disease
MELBOURNE, Australia and SAN FRANCISCO, USA, August 12, 2026 Alterity Therapeutics Limited announced that the U.S. Patent and Trademark...
Advertisement
